A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)
Status:
Completed
Trial end date:
2020-10-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the Maximum Tolerated Dose (MTD) of pralatrexate in
combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen in
patients with newly diagnosed peripheral T-cell lymphoma (PTCL).